Unknown

Dataset Information

0

High platelet-to-lymphocyte ratio is associated with poor prognosis in patients with unresectable intrahepatic cholangiocarcinoma receiving gemcitabine plus cisplatin.


ABSTRACT: BACKGROUND:Several systemic inflammatory response (SIR) markers, including platelet-to-lymphocyte ratio (PLR), neutrophil-to-lymphocyte ratio (NLR), lymphocyte-to-monocyte ratio (LMR), and albumin-to-globulin ratio (AGR), have emerged as prognostic markers in various cancers. The aim of this study was to explore the impact of SIR markers on the survival outcomes of unresectable intrahepatic cholangiocarcinoma (IHC) patients. METHODS:Patients with histologically confirmed, unresectable IHC treated with gemcitabine plus cisplatin (GP) chemotherapy in a single tertiary hospital from 2012 to 2016 were retrospectively reviewed. Progression-free survival (PFS) and overall survival (OS) were determined using unadjusted Kaplan-Meier and adjusted Cox-proportional-hazards analysis. Time-dependent receiver operating characteristic (ROC) analysis was performed to compare the performance of the SIR markers in predicting OS. RESULTS:A total of 137 patients received a median of six cycles (interquartile range [IQR], 3-11) of GP chemotherapy with a median observation time of 9.9?months (range, 1.8-54.7?months). The median PFS and OS of all patients were 7.8?months and 9.9?months, respectively. Among the SIR markers, high PLR (>?148) and high NLR (>?5) were associated with a short PFS (Hazard ratio [HR] 1.828, P =?0.006; HR 1.738, P =?0.030, respectively) and short OS (HR 2.332, P 

SUBMITTER: Huh G 

PROVIDER: S-EPMC7510111 | BioStudies | 2020-01-01

REPOSITORIES: biostudies

Similar Datasets

1000-01-01 | S-EPMC5907660 | BioStudies
1000-01-01 | S-EPMC5719445 | BioStudies
1000-01-01 | S-EPMC5355064 | BioStudies
2019-01-01 | S-EPMC6914857 | BioStudies
1000-01-01 | S-EPMC5711862 | BioStudies
2019-01-01 | S-EPMC6380854 | BioStudies
2019-01-01 | S-EPMC6744413 | BioStudies
1000-01-01 | S-EPMC5895303 | BioStudies
1000-01-01 | S-EPMC6090788 | BioStudies
2020-01-01 | S-EPMC6951460 | BioStudies